PT3439665T - Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5 - Google Patents

Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5

Info

Publication number
PT3439665T
PT3439665T PT177677010T PT17767701T PT3439665T PT 3439665 T PT3439665 T PT 3439665T PT 177677010 T PT177677010 T PT 177677010T PT 17767701 T PT17767701 T PT 17767701T PT 3439665 T PT3439665 T PT 3439665T
Authority
PT
Portugal
Prior art keywords
alpha5
neurodegenerative
cognitive
treatment
receptor agonists
Prior art date
Application number
PT177677010T
Other languages
English (en)
Original Assignee
Uwm Res Foundation Inc
Univ Of Belgrade Faculty Of Pharmacy
Camh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uwm Res Foundation Inc, Univ Of Belgrade Faculty Of Pharmacy, Camh filed Critical Uwm Res Foundation Inc
Publication of PT3439665T publication Critical patent/PT3439665T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
PT177677010T 2016-03-18 2017-03-20 Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5 PT3439665T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662310409P 2016-03-18 2016-03-18

Publications (1)

Publication Number Publication Date
PT3439665T true PT3439665T (pt) 2022-09-27

Family

ID=59851645

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177677010T PT3439665T (pt) 2016-03-18 2017-03-20 Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5

Country Status (15)

Country Link
US (3) US10906909B2 (pt)
EP (2) EP4129297A1 (pt)
JP (2) JP7023876B2 (pt)
AU (2) AU2017235665B2 (pt)
CA (1) CA3016491A1 (pt)
DK (1) DK3439665T3 (pt)
ES (1) ES2926918T3 (pt)
HR (1) HRP20221098T1 (pt)
HU (1) HUE059774T2 (pt)
LT (1) LT3439665T (pt)
PL (1) PL3439665T3 (pt)
PT (1) PT3439665T (pt)
RS (1) RS63674B1 (pt)
SI (1) SI3439665T1 (pt)
WO (1) WO2017161370A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017313753B2 (en) 2016-08-16 2022-01-27 The Trustees Of Columbia University In The City Of New York GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma
CA3129749A1 (en) * 2019-02-13 2020-08-20 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
CN113840610A (zh) * 2019-03-18 2021-12-24 纽罗塞克医疗公司 Gabaa受体调节剂用于治疗疼痛的用途
TW202202495A (zh) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物
WO2023039018A1 (en) * 2021-09-08 2023-03-16 Uwm Research Foundation, Inc. Imidazobenzodiazepines for treatment of cognitive and mood symptoms
HUP2100338A1 (hu) 2021-09-29 2023-04-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CA3233966A1 (en) * 2021-10-07 2023-04-13 Douglas C. Stafford Methods and compounds for treating inflammation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA755418B (en) * 1974-09-11 1977-06-29 Hoffmann La Roche Diazepine derivatives
US4226768A (en) 1979-05-29 1980-10-07 Hoffmann-La Roche Inc. Process for the preparation of imidazobenzodiazepines
US20030176456A1 (en) 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
AU2003230754B2 (en) 2002-03-28 2007-10-25 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
USRE47475E1 (en) 2002-03-28 2019-07-02 Wisys Technology Foundation, Inc. Selective agents for pain suppression
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
US7618958B2 (en) 2004-06-30 2009-11-17 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
AU2006276998A1 (en) * 2005-05-16 2007-02-15 Wisys Technology Foundation, Inc. Gabaergic agents to treat memory deficits
US20100130479A1 (en) 2005-05-16 2010-05-27 Cook James M Gabaergic Agents to Treat Memory Deficits
US7858649B2 (en) 2005-10-14 2010-12-28 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
DE102006023554A1 (de) 2006-05-19 2007-11-22 Zf Friedrichshafen Ag Ermittlung der Drehzahl einer Getriebewelle
US8119629B2 (en) * 2007-10-03 2012-02-21 Bristol-Meyers Squibb Company Carboxamide GABAA α2 modulators
EP2364571B1 (en) 2008-10-02 2012-08-22 Telefonaktiebolaget L M Ericsson (PUBL) Wireless communication system and method for assigning a channel in said wireless communication system
US20100261711A1 (en) 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
US9006233B2 (en) 2011-04-28 2015-04-14 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
WO2014047413A1 (en) 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
US10259815B2 (en) 2015-03-20 2019-04-16 Uwm Research Foundation, Inc. Gabaergic ligands and their uses

Also Published As

Publication number Publication date
ES2926918T3 (es) 2022-10-31
LT3439665T (lt) 2022-10-10
EP3439665A1 (en) 2019-02-13
AU2017235665B2 (en) 2022-12-08
US20210309662A1 (en) 2021-10-07
AU2017235665A1 (en) 2018-09-27
US20200181146A1 (en) 2020-06-11
SI3439665T1 (sl) 2023-05-31
US20240083905A1 (en) 2024-03-14
HRP20221098T1 (hr) 2022-11-25
RS63674B1 (sr) 2022-11-30
EP3439665A4 (en) 2019-11-27
WO2017161370A1 (en) 2017-09-21
EP3439665B1 (en) 2022-06-29
US11753412B2 (en) 2023-09-12
JP2019509340A (ja) 2019-04-04
PL3439665T3 (pl) 2023-01-16
WO2017161370A8 (en) 2018-09-27
EP4129297A1 (en) 2023-02-08
JP7023876B2 (ja) 2022-02-22
CA3016491A1 (en) 2017-09-21
DK3439665T3 (da) 2022-09-26
HUE059774T2 (hu) 2023-01-28
US10906909B2 (en) 2021-02-02
JP2022065035A (ja) 2022-04-26
AU2022275446A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
PT3439665T (pt) Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5
ZA201804458B (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
IL290985A (en) Methods for diagnosing and treating anxiety disorder
IL259422A (en) Pharmaceutical contraceptives against stress-induced emotional disorders and their associated symptoms
IL266652A (en) Subpopulation quantification of exosomes and diagnosis of neurodegenerative disorders
HK1254030A1 (zh) 治療自身免疫病症和同種免疫病症的方法
EP2996771A4 (en) TREATMENT OF HUMILION AND FEAR STROKES
HK1232289A1 (zh) 分揀蛋白作為針對情感/心境障礙的生物標記的用途
PT2977056T (pt) Transferrina para usar no tratamento de distúrbios neurodegenerativos relacionados com o factor induzido por hipoxia (fih)
IL269604A (en) Pentides for the treatment of autoimmune diseases
PT3250600T (pt) Tratamento de distúrbios autoimunes com anticorpos anti-cd154
IL262135A (en) Methods of treatment with selective cb2 receptor agonists
SG11201708657XA (en) Short synthetic peptide for treatment and/or prophylaxis of autoimmune and inflammatory disorders
IL249485B (en) History of o-alkyl-benzylideneguanidine and therapeutic use for the treatment of disorders associated with the accumulation of misfolded proteins
SG10201913129QA (en) Treatment and diagnosis of inflammatory disorders
ITUA20161679A1 (it) Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
GB201411616D0 (en) Diagnosis and treatment of neurodegenerative disorders
EP3423049C0 (en) METHODS OF TREATMENT OR RELIEF OF MENTAL DISORDERS AND ASSOCIATED SYMPTOMS
IL252043A0 (en) A proline-rich polypeptide complex for use in the treatment of brain neurotrophic factor-related disorders
IL248381A0 (en) A combination of brexpiprazole and nalemapine and its use in the treatment of drug-related disorders
TH1501005802A (th) องค์ประกอบกาแลคโตโอลิโกแซคคาไรด์สำหรับใช้ในการป้องกัน หรือรักษาความผิดปกติในการรับรู้และความผันแปรทางอารมณ์ในการเจ็บป่วย ทางจิตประสาทหรือความชรา
AU2015905047A0 (en) Methods of treating or alleviating mental disorders and associated symptoms
MA40969A (fr) Peptide homodimérique pour le traitement du diabète et des maladies liées
GB201418096D0 (en) Novel polymorph for use in treatment of inflammatory skin and pruritic disorders
GB201516418D0 (en) Treatment of acute inflammatory disorders